The Comprehensive Prohost Letter Issues

The Comprehensive Prohost Letter Issues will constitute a chain of 7 issues.

Today’s issue will include the following:

• Pinpointing and selecting the biotech firms that demonstrate readiness to treat untreatable, devastating diseases.

• Presenting an important antibody cocktail for the treatment of COVID-19.

• Stating our position regarding the Alzheimer’s disease firm Cassava Sciences.

• Pinpointing Prohost’s . . .

  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Prohost Letters

  Akero Therapeutics (AKRO), Cassava Sciences (SAVA), Celldex Therapeutics (CLDX), Compugen (CGEN), CRISPR Therapeutics (CRSP), Editas Medicine Inc (EDIT), Intellia Therapeutics (NTLA), IVERIC bio (ISEE), Jounce Therapeutics (JNCE), Prohost Portfolio, Reata Pharmaceuticals (RETA), Regeneron Pharmaceuticals (REGN), Regenxbio (RGNX), SARS-CoV-2 (the virus that causes COVID-19), Vir Biotechnology (VIR)

  September 19, 2021
  Tweet Pin It